Last reviewed · How we verify
latanoprost 0.0025% QD
At a glance
| Generic name | latanoprost 0.0025% QD |
|---|---|
| Sponsor | Inotek Pharmaceuticals Corporation |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of Fixed-Dose Combinations of Trabodenoson and Latanoprost in Adults With OHT or POAG (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |